JTJürg Tschopp

Jürg Tschopp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jürg Tschopp has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Pascal Schneider

    Department of Immunobiology, University of Lausanne, Epalinges, Switzerland

    11 shared publications
  • Kay Hofmann

    5 shared publications
  • Lars Einar French

    Department of Dermatology and Allergy University Hospital, LMU Munich Munich Germany

    5 shared publications
  • Nils Holler

    From the ‡Institute of Biochemistry, University of Lausanne, 155 Chemin des Boveresses, CH-1066 Epalinges, Switzerland, the ¶Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Quebec H9R 4P8, Canada, and the ‖Institute of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

    5 shared publications
  • Fabio Martinon

    Department of Immunobiology, University of Lausanne, 155 Ch. des Boveresses, 1066 Epalinges, Switzerland

    4 shared publications
  • Margot Thome

    Department of Immunobiology, University of Lausanne, Epalinges, Switzerland

    4 shared publications

Latest Publications

  • Modulation of death receptor signalling

    by Pascal Schneider, Jürg Tschopp

    The death domain-containing members of the TNF receptor family mediate apoptosis upon engagement by their respective ligands. The aggregation of the receptors allows the recruitment of intracellular adaptor proteins which in turn interact with and activate members of the caspase family by means of distinct protein-protein interaction domains, ultimately leading to apoptosis. The central event of apoptotic cell death is the proteolytic activation of intracellular cysteine proteases, called the caspases that pre-exist in the cell as inactive zymogen precursors. The death domain is a homotypic protein-protein interaction domain of about 90 amino acids, which allows the recruitment of adaptator proteins to the activated receptor. Similarly, two related domains have been identified that promote the protein-protein interactions within the apoptotic-signalling pathway, namely the death effector domain and the caspase recruitment domain. Many of the interactions leading to caspase activation proceed via homotypic interactions of these domains.

  • The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress

    by Antoine Tinel, JürG Tschopp

    Apoptosis is triggered by activation of initiator caspases upon complex-mediated clustering of the inactive zymogen, as occurs in the caspase-9–activating apoptosome complex. Likewise, caspase-2, which is involved in stress-induced apoptosis, is recruited into a large protein complex, the molecular composition of which remains elusive. We show that activation of caspase-2 occurs in a complex that contains the death domain–containing protein PIDD, whose expression is induced by p53, and the adaptor protein RAIDD. Increased PIDD expression resulted in spontaneous activation of caspase-2 and sensitization to apoptosis by genotoxic stimuli. Because PIDD functions in p53-mediated apoptosis, the complex assembled by PIDD and caspase-2 is likely to regulate apoptosis induced by genotoxins.


  • NALPs: a novel protein family involved in inflammation

    by Jürg Tschopp, Fabio Martinon, Kimberly Burns

    On infection, microorganisms are efficiently recognized by Toll-like receptors (TLRs), which recognize invariant molecular structures called pathogen-associated molecular patterns (PAMPs) that are shared by many pathogens but are not expressed by their hosts. Recognition of PAMPs by TLRs results in the activation of different intracellular signalling cascades, which, in turn, lead to the expression of various effector molecules. One of these, interleukin-1β (IL-1β), is defined as an 'alarm cytokine'; it is secreted by macrophages and initiates inflammation. For IL-1β to be active, pro-IL-1β must first be processed to an active molecule and then secreted. The IL-1β-converting enzyme (ICE) — also known as caspase-1 — is responsible for this processing. A novel family of cytoplasmic proteins containing NACHT, leucine-rich domains and either a Pyrin or CARD domain are involved in caspase-1 activation and therefore IL-1β cleavage. One member of this family, designated NALP1, assembles into a complex with ASC, caspase-1 and caspase-5, forming the 'inflammasome'. The NALP3 gene is mutated in three related autosomal-dominant autoinflammatory disorders, Muckle–Wells syndrome, familial cold urticaria, and in chronic infantile neurologic cutaneous and articular syndrome.


  • Open Access

    Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4

    by Kimberly Burns, Sophie Janssens, Brian Brissoni, Natalia Olivos, Rudi Beyaert, JürG Tschopp

    Toll-like receptors (TLRs) and members of the proinflammatory interleukin 1 receptor (IL-1R) family are dependent on the presence of MyD88 for efficient signal transduction. The bipartite nature of MyD88 (N-terminal death domain [DD] and COOH-terminal Toll/IL-1 receptor [TIR] domain) allows it to link the TIR domain of IL-1R/TLR with the DD of the Ser/Thr kinase termed IL-1R–associated kinase (IRAK)-1. This triggers IRAK-1 phosphorylation and in turn the activation of multiple signaling cascades such as activation of the transcription factor nuclear factor (NF)-κB. In contrast, expression of MyD88 short (MyD88s), an alternatively spliced form of MyD88 that lacks only the short intermediate domain separating the DD and TIR domains, leads to a shutdown of IL-1/lipopolysaccharide-induced NF-κB activation. Here, we provide the molecular explanation for this difference. MyD88 but not MyD88s strongly interacts with IRAK-4, a newly identified kinase essential for IL-1R/TLR signaling. In the presence of MyD88s, IRAK-1 is not phosphorylated and neither activates NF-κB nor is ubiquitinated. Thus, MyD88s acts as a negative regulator of IL-1R/TLR/MyD88-triggered signals, leading to a transcriptionally controlled negative regulation of innate immune responses.


  • Open Access

    RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF‐κB and is processed during apoptosis

    by Etienne Meylan, Fabio Martinon, Margot Thome, Michael Gschwendt, Jürg Tschopp

    RIP1 and its homologs, RIP2 and RIP3, form part of a family of Ser/Thr kinases that regulate signal transduction processes leading to NF‐κB activation. Here, we identify RIP4 (DIK/PKK) as a novel member of the RIP kinase family. RIP4 contains an N‐terminal RIP‐like kinase domain and a C‐terminal region characterized by the presence of 11 ankyrin repeats. Overexpression of RIP4 leads to activation of NF‐κB and JNK. Kinase inactive RIP4 or a truncated version containing the ankyrin repeats have a dominant negative (DN) effect on NF‐κB induction by multiple stimuli. RIP4 binds to several members of the TRAF protein family, and DN versions of TRAF1, TRAF3 and TRAF6 inhibit RIP4‐induced NF‐κB activation. Moreover, RIP4 is cleaved after Asp340 and Asp378 during Fas‐induced apoptosis. These data suggest that RIP4 is involved in NF‐κB and JNK signaling and that caspase‐dependent processing of RIP4 may negatively regulate NF‐κB‐dependent pro‐survival or pro‐inflammatory signals.


  • Open Access

    The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex

    by Olivier Micheau, Margot Thome, Pascal Schneider, Nils Holler, Jürg Tschopp, Donald W. Nicholson, Christophe Briand, Markus G. Grütter


  • The Caspase 8 Inhibitor c-FLIPL Modulates T-Cell Receptor-Induced Proliferation but Not Activation-Induced Cell Death of Lymphocytes

    by Susanne M. A. Lens, Takao Kataoka, Karen A. Fortner, Antoine Tinel, Isabel Ferrero, Robson H. MacDonald, Michel Hahne, Friedrich Beermann, Antoine Attinger, Hans-Acha Orbea, et al.

    The t(8;21)(q22;q22) translocation, which fuses the ETO gene on human chromosome 8 with the AML1 gene on chromosome 21 (AML1-ETO), is one of the most frequent cytogenetic abnormalities associated with acute myelogenous leukemia (AML). It is seen in approximately 12 to 15% of AML cases and is present in about 40% of AML cases with a French-American-British classified M2 phenotype. We have generated a murine model of the t(8;21) translocation by retroviral expression of AML1-ETO in purified hematopoietic stem cells (HSC). Animals reconstituted with AML1-ETO-expressing cells recapitulate the hematopoietic developmental abnormalities seen in the bone marrow of human patients with the t(8;21) translocation. Primitive myeloblasts were increased to approximately 10% of bone marrow by 10 months posttransplant. Consistent with this observation was a 50-fold increase in myeloid colony-forming cells in vitro. Accumulation of late-stage metamyelocytes was also observed in bone marrow along with an increase in immature eosinophilic myelocytes that showed abnormal basophilic granulation. HSC numbers in the bone marrow of 10-month-posttransplant animals were 29-fold greater than in transplant-matched control mice, suggesting that AML1-ETO expression overrides the normal genetic control of HSC pool size. In summary, AMLI-ETO-expressing animals recapitulate many (and perhaps all) of the developmental abnormalities seen in human patients with the t(8;21) translocation, although the animals do not develop leukemia or disseminated disease in peripheral tissues like the liver or spleen. This suggests that the principal contribution of AML1-ETO to acute myeloid leukemia is the inhibition of multiple developmental pathways.


  • Open Access

    Maturation of Marginal Zone and Follicular B Cells Requires B Cell Activating Factor of the Tumor Necrosis Factor Family and Is Independent of B Cell Maturation Antigen

    by Pascal Schneider, Hisakazu Takatsuka, Anne Wilson, Fabienne Mackay, Aubry Tardivel, Susanne Lens, Teresa G. Cachero, Daniela Finke, Friedrich Beermann, Jürg Tschopp

    B cells undergo a complex series of maturation and selection steps in the bone marrow and spleen during differentiation into mature immune effector cells. The tumor necrosis factor (TNF) family member B cell activating factor of the TNF family (BAFF) (BLyS/TALL-1) plays an important role in B cell homeostasis. BAFF and its close homologue a proliferation-inducing ligand (APRIL) have both been shown to interact with at least two receptors, B cell maturation antigen (BCMA) and transmembrane activator and cyclophilin ligand interactor (TACI), however their relative contribution in transducing BAFF signals in vivo remains unclear. To functionally inactivate both BAFF and APRIL, mice transgenic for a soluble form of TACI were generated. They display a developmental block of B cell maturation in the periphery, leading to a severe depletion of marginal zone and follicular B2 B cells, but not of peritoneal B1 B cells. In contrast, mice transgenic for a soluble form of BCMA, which binds APRIL, have no detectable B cell phenotype. This demonstrates a crucial role for BAFF in B cell maturation and strongly suggests that it signals via a BCMA-independent pathway and in an APRIL-dispensable way.


  • NF-κB Signals Induce the Expression of c-FLIP

    by Olivier Micheau, Susanne Lens, Olivier Gaide, Kostis Alevizopoulos, Jürg Tschopp

    Activation of the transcription factor NF-κB is a major effector of the inducible resistance to death receptor-mediated apoptosis. Previous evidence indicates that the combined transcriptional activation of TRAF-1, TRAF-2, IAP-1, and IAP-2 is required to suppress cell death by tumor necrosis factor (TNF). Here we show that NF-κB activation upregulates the caspase 8 inhibitor FLIP, resulting in increased resistance to Fas ligand (FasL) or TNF. Restoration of either the full-length 55-kDa long form of FLIP or an alternatively spliced short form of FLIP in NF-κB null cells inhibits TNF- and FasL-induced cell death efficiently, whereas the expression of IAP or TRAF family members only partially rescues cells from death. Resistance to either FasL- or TNF-induced apoptosis is overcome when cells are incubated in the presence of the protein synthesis inhibitor cycloheximide. This treatment leads to the rapid downregulation of FLIP but not to that of TRAF2. Our findings suggest that FLIP is an important mediator of NF-κB-controlled antiapoptotic signals.